Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Livagen cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established Livagen cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Livagen combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Livagen cycle length?
No. We found no human studies that report a treatment duration for Livagen.
What is the longest human study of Livagen?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Livagen dosing reference Full research page

References

  1. Livagen [Supplementary Concept] — entry terms lysyl-glutamyl-aspartylalanine, Lys-Glu-Asp-Ala Medical Subject Headings, U.S. National Library of Medicine. 2026
  2. Livagen (CID 87919683) — compound record, C18H31N5O9, 461.5 g/mol, CAS 433257-50-2 PubChem, U.S. National Library of Medicine. 2026
  3. Effects of Livagen peptide on chromatin activation in lymphocytes from old people Bulletin of Experimental Biology and Medicine. 2002
  4. Effects of short peptides on lymphocyte chromatin in senile subjects Bulletin of Experimental Biology and Medicine. 2004
  5. Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals Annals of the New York Academy of Sciences. 2007
  6. Genomic instability in atherosclerosis (in Russian) Georgian Medical News. 2014
  7. Epigenetic modification under the influence of peptide bioregulators on the “old” chromatin Georgian Medical News. 2023
  8. Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages (in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2005
  9. Tissue-specific effects of peptides Bulletin of Experimental Biology and Medicine. 2001
  10. The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology (review, in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2020
  11. Evaluation of genomic parameters in ductal breast cancer patients and the ability of its correction (in Russian) Georgian Medical News. 2017
  12. ClinicalTrials.gov registry query for "livagen" (0 studies returned) ClinicalTrials.gov (U.S. National Library of Medicine). 2026
  13. openFDA Drug Label API query for "livagen" (no approved human drug labeling for a peptide of this name) U.S. Food and Drug Administration / openFDA. 2026
  14. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) U.S. Food and Drug Administration. 2026
  15. World Anti-Doping Code International Standard — Prohibited List 2026 (effective 1 January 2026) World Anti-Doping Agency. 2026
  16. PubMed query for "livagen" (19 records) PubMed / NCBI Entrez (U.S. National Library of Medicine). 2026